Abstract
OBJECTIVE: This study involved evaluating the efficacy of the Feijinsheng formula in the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC). METHODS: We extracted the medical records of patients with advanced NSCLC undergoing treatment in the oncology department at the Second Affiliated Hospital of Zhejiang Chinese Medicine University from the medical record system. After applying inclusion and exclusion criteria, clinical data of 150 patients were collected. The patients were stratified into two groups based on their usage of the Feijinsheng formula, comprising 69 cases in the Exposed group and 81 cases in the Control group. A comparative analysis of the survival time difference between the two groups was conducted. RESULTS: The data between the two groups exhibited similarity (p > 0.05). Following treatment, the Exposed group demonstrated a notably prolonged overall survival time compared to the Control group (p < 0.05). While the Exposed group displayed a higher objective remission rate than the Control group, this disparity did not reach statistical significance (p > 0.05). CONCLUSION: The Feijinsheng formula extended the duration of survival of patients with advanced NSCLC.